Evidence map›Paper›PMID 23612964›Full record

ArticleThe Journal of biological chemistry2013

Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants.

Ying-Xin Fan, Lily Wong, Michael P Marino, Wu Ou, Yi Shen, Wen Jin Wu, Kwok-Kin Wong, Jakob Reiser, Gibbes R Johnson

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Ying-Xin FanDivision of Therapeutic Proteins, Center for Drug Evaluation and Research, Bethesda, Maryland 20892. Electronic address: ying-xin.fan@fda.hhs.gov.
Lily WongDivision of Therapeutic Proteins, Center for Drug Evaluation and Research, Bethesda, Maryland 20892.
Michael P MarinoDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Bethesda, Maryland 20892.
Wu OuDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Bethesda, Maryland 20892.
Yi ShenDivision of Monoclonal Antibodies, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892.
Wen Jin WuDivision of Monoclonal Antibodies, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892.
Kwok-Kin WongDepartment of Medicine, Harvard Medical School, Boston, Massachusetts 02115.
Jakob ReiserDivision of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Bethesda, Maryland 20892.
Gibbes R JohnsonDivision of Therapeutic Proteins, Center for Drug Evaluation and Research, Bethesda, Maryland 20892. Electronic address: gibbes.johnson@fda.hhs.gov.
Center for Drug Evaluation and Research · USCenter for Biologics Evaluation and Research · USHarvard University · US

Funding

StructureP01CA154303 · NCI · DANA-FARBER CANCER INST · PI JANNE, PASI A · 2012 to 2021
$17.8M
MUC1-C Oncoprotein Evades Immune Destruction in Non-small Cell Lung CancerR01CA166480 · NCI · DANA-FARBER CANCER INST · PI KUFE, DONALD W., WONG, KWOK KIN · 2012 to 2021
$6.3M
Therapeutic strategies for specific subsets of KRAS mutant lung cancersR01CA140594 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WONG, KWOK KIN · 2009 to 2017
$4.5M
In vivo analysis of EGFR mutant driven lung cancers responses to radiation therapR01CA122794 · NCI · DANA-FARBER CANCER INST · PI WONG, KWOK KIN · 2006 to 2015
$2.8M
NCI NIH HHS P01 CA154303NCI NIH HHS R01 CA122794NCI NIH HHS R01 CA140594NCI NIH HHS R01 CA166480
6 · The paper itself

Abstract

Activating mutations in the αC-β4 loop of the ERBB2 kinase domain, such as ERBB2(YVMA) and ERBB2(G776VC), have been identified in human lung cancers and found to drive tumor formation. Here we observe that the docking protein GAB1 is hyper-phosphorylated in carcinomas from transgenic mice and in cell lines expressing these ERBB2 cancer mutants. Using dominant negative GAB1 mutants lacking canonical tyrosine residues for SHP2 and PI3K interactions or lentiviral shRNA that targets GAB1, we demonstrate that GAB1 phosphorylation is required for ERBB2 mutant-induced cell signaling, cell transformation, and tumorigenesis. An enzyme kinetic analysis comparing ERBB2(YVMA) to wild type using physiologically relevant peptide substrates reveals that ERBB2(YVMA) kinase adopts a striking preference for GAB1 phosphorylation sites as evidenced by ∼150-fold increases in the specificity constants (kcat/Km) for several GAB1 peptides, and this change in substrate selectivity was predominantly attributed to the peptide binding affinities as reflected by the apparent Km values. Furthermore, we demonstrate that ERBB2(YVMA) phosphorylates GAB1 protein ∼70-fold faster than wild type ERBB2 in vitro. Notably, the mutation does not significantly alter the Km for ATP or sensitivity to lapatinib, suggesting that, unlike EGFR lung cancer mutants, the ATP binding cleft of the kinase is not significantly changed. Taken together, our results indicate that the acquired substrate preference for GAB1 is critical for the ERBB2 mutant-induced oncogenesis.

Indexed as

Mutation, MissenseAdaptor Proteins, Signal TransducingAdenosine TriphosphateAmino Acid SubstitutionAnimalsAntineoplastic AgentsCell Transformation, NeoplasticErb-b2 Receptor Tyrosine KinasesFemaleHumansLapatinibLung NeoplasmsMiceMice, NudeMice, TransgenicPhosphatidylinositol 3-KinasesAdaptor Proteins, Signal TransducingAdenosine TriphosphateAntineoplastic AgentsERBB2 protein, humanErbb2 protein, mouseErb-b2 Receptor Tyrosine KinasesGAB1 protein, humanGab1 protein, mouseLapatinibPhosphatidylinositol 3-KinasesPhosphoproteinsProtein Tyrosine Phosphatase, Non-Receptor Type 11Ptpn11 protein, mouseQuinazolinesAdaptor ProteinsEnzyme MechanismsEpidermal Growth Factor Receptor (EGFR)ERBB2/HER2GAB1Lung CancerOncogenic MutationTyrosine-protein Kinase (Tyrosine Kinase)

Identifiers

PMID23612964
PMCPMC3675622
OpenAlexW1965352336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.